Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 12/20 | 0.60 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708144 | 0.90 | LPAR1 (0.49) | LPAR1LPAR3TUBB1HTTFFAR1 | |
| SCHEMBL709264 | 0.85 | LPAR1 (0.61) | LPAR1LPAR3LPAR2TUBB1LPAR5 | |
| SCHEMBL27779240 | 0.84 | TUBB1 (0.47) | LPAR1TUBB1HTTLMNASMN1; SMN2 | |
| SCHEMBL708137 | 0.83 | LPAR1 (0.65) | LPAR1LPAR3LPAR2TUBB1LPAR5 | |
| SCHEMBL709015 | 0.78 | LPAR1 (0.53) | LPAR1LPAR3TUBB1HTTFFAR1 | |
| SCHEMBL968828 | 0.76 | LPAR1 (0.58) | LPAR1LPAR3LPAR2TUBB1LPAR5 | |
| SCHEMBL708862 | 0.76 | LPAR1 (0.71) | LPAR1LPAR3LPAR2LPAR5 | |
| SCHEMBL971639 | 0.75 | LPAR1 (0.61) | LPAR1LPAR3LPAR2LPAR5 | |
| SCHEMBL710010 | 0.75 | LPAR1 (1.00) | LPAR1LPAR3LPAR2LPAR5 | |
| SCHEMBL968829 | 0.73 | LPAR1 (0.60) | LPAR1LPAR3LPAR2TUBB1LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589123-B2 | Chemical compounds | PHYTOPHARM PLC (GB) | 2009-09-15 | — | — | US | claimed |
| EP-2046311-A2 | DIOXO-ALKANES AND DIOXO-ALKENES | Phytopharm Plc (GB) | 2009-04-15 | — | — | EP | claimed |
| US-20080045591-A1 | Chemical Compounds | VECTURA LIMITED (GB) | 2008-02-21 | — | — | US | claimed |
| WO-2008003978-A2 | DIOXO-ALKANES AND DIOXO-ALKENES | PHYTOPHARM PLC (GB) | 2008-01-10 | — | — | WO | claimed |
| EP-1553075-B1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2565178-A1 | LPA Receptor Antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8124645-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-7820682-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7589123-B2 | Chemical compounds | PHYTOPHARM PLC (GB) | 2009-09-15 | — | — | US | disclosed |
| CN-101511350-A | Dioxo-alkanes and dioxo-alkenes | PHYTOPHARM PLC (GB) | 2009-08-19 | — | — | CN | disclosed |
| EP-2046311-A2 | DIOXO-ALKANES AND DIOXO-ALKENES | Phytopharm Plc (GB) | 2009-04-15 | — | — | EP | disclosed |
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. | 2008-11-27 | — | — | US | disclosed |
| US-20080045591-A1 | Chemical Compounds | VECTURA LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| WO-2008003978-A2 | DIOXO-ALKANES AND DIOXO-ALKENES | PHYTOPHARM PLC (GB) | 2008-01-10 | — | — | WO | disclosed |
| US-20060148830-A1 | Lpa receptor antagonist | ONO PHARMACEUTICAL CO., LTD. | 2006-07-06 | — | — | US | disclosed |
| EP-1553075-A1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885LPAR2 2/4885 |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885LPAR2 2/4885 |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885LPAR2 2/4885 |
| US-20080045591-A1 | Chemical Compounds | CYP11B1, CYP11B2, CYP2S1 | LPAR1 1812/4885LPAR3 1532/4885LPAR2 1783/4885 |
| US-20060148830-A1 | Lpa receptor antagonist | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885LPAR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.